Gedivumab
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies[1].
Product Specifications
CAS Number
1807954-17-1
Product Name Alternative
MHAA4549A; RG7745
UNSPSC
12352203
Target
Influenza Virus
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/gedivumab.html
Purity
95.11
Solubility
10 mM in DMSO
Smiles
[Gedivumab]
Molecular Weight
(146.62 kDa)
References & Citations
[1]Jeremy J Lim, et al. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers. Antimicrob Agents Chemother. 2016 Aug 22;60 (9) :5437-44.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ARP74195_P050-FITC 100 µL
RTEL1 Antibody - C-terminal region : FITC (ARP74195_P050-FITC)
Sign In for Pricing
View Details MBS1244268-01 0.02 mg (E-Coli)
Recombinant Haemophilus somnus GTP cyclohydrolase-2 (ribA)
Sign In for Pricing
View Details MBS1244268-02 0.1 mg (E-Coli)
Recombinant Haemophilus somnus GTP cyclohydrolase-2 (ribA)
Sign In for Pricing
View Details